Quick Overview: OBAs (outcome-based agreements) can bring In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two experts on reimbursement-facing evidence ... Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss a new study showing some cancer

Accelerated Drug Access Risks And - Detailed Overview & Context

OBAs (outcome-based agreements) can bring In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two experts on reimbursement-facing evidence ... Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss a new study showing some cancer Tune in as Glenn Hunzinger, PwC's Health Industries Leader, connects with Matt Rich, PwC's Pharma and Life Sciences R&D ... Beth Galliart, co-founder of Iclusig Patient Group, recently spoke to us at our Cancer Policy Policy Roundtable in April of 2014. Dr Maurie Markman discusses beneficial outcomes of the FDA

On 8 May 2026, CPE hosted the webinar "The Price of New research being conducted in San Antonio may soon bring hope to people battling different forms of cancer. Tasmanian mother-of-three Lauren Rayner was given 14 months to live when she was diagnosed with a rare and aggressive form ... Dr. Cliff, of Harvard Medical School and Brigham and Women's Hospital, spoke with Blood Cancers Today to describe an analysis ... Huseyin Naci, Associate Professor of Health Policy at the London School of Economics, discusses his recent research about ...

Photo Gallery

Accelerated drug access - risks and rewards
What is Accelerated Approval?
Many cancer drugs remain unproven 5 yrs after accelerated approval: Study
Anja Schiel & Nicholas Hedberg: Accelerated Approvals, Evidence Gaps, and Reimbursement Risk
FDA Drug Info Rounds, July 2012: Accelerated Approval Program
The Dark Side of Fast-Tracked Cancer Drugs
Expanded Access
Fast-tracked cancer drugs prove ineffective, study finds
Some cancer drugs remain unproven 5 years after FDA's accelerated approval, study finds
Navigating the FDA disruption: 4 key actions for pharma
Advocacy Grand Rounds: Accelerated Approval Reforms: Balancing Timely Access & True Clinical Benefit
Beth Galliart Discusses Risk and Benefit in Cancer Drugs
Sponsored
Sponsored
View Main Result
Sponsored
Sponsored